ガイドラインに沿った 大腸癌化学療法の要点と盲点

出版社: 文光堂
著者:
発行日: 2014-11-01
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784830618871
電子書籍版: 2014-11-01 (第1版第3刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

8,250 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,250 円(税込)

商品紹介

[大腸癌治療ガイドライン 医師用2014年版]に記載されている化学療法に準拠し,実践に応用するためのコツ,レジメンの実践的な使い方,ガイドラインの行間を埋める知識を盛り込んだ,大腸癌化学療法の決定版.臨床で疑問に思った事柄の解決の参考になるよう,大腸癌化学療法のエクスパートの叡智が集結した1冊.

目次

  • ガイドラインに沿った 大腸癌化学療法の要点と盲点

    ―目次―

    I 総論
     1. 切除不能進行再発大腸癌化学療法の標準的治療
     2. 大腸癌治療ガイドライン2014年版アルゴリズムの解説

    II 副作用マネジメント
     1. 大腸癌化学療法で起こり得る副作用と予防・対処法
      1) 白血球減少・好中球減少,血小板減少
      2) 悪心・嘔吐
      3) 口腔粘膜炎
      4) 下痢
      5) 手足症候群
      6) 抗EGFR抗体薬による皮膚障害
      7) 末梢神経障害
      8) アレルギー反応
      9) インフュージョンリアクション
      10) 間質性肺炎
      11) 肝機能障害
      12) 電解質異常
      13) その他の注意すべき副作用
     2. 副作用による休薬,投与量変更

    III 治療変更の考え方
     1. 副作用による治療変更
     2. PDによる治療変更
     3. 効果が持続しているときの治療変更

    IV 各論
     1. 各種レジメンの実際
      1) FOLFOX+Bmab,CapeOX+Bmab,SOX+Bmab
      2) FOLFIRI+Bmab
      3) FOLFOX+Cmab/Pmab
      4) FOLFIRI+Cmab/Pmab
      5) irinotecan 抵抗性に対するirinotecan+Cmab/Pmab
      6) FOLFOXIRI(+Bmab)
      7) sLV5FU2+Bmab,capecitabine+Bmab
      8) レゴラフェニブ(regorafenib:スチバーガ?)
      9) IRIS療法
     2. 一次治療をどのように選択して二次治療以降を
        どのように考えていくか?
      1) 一次治療としてFOLFOX/CapeOX+Bmab 療法を行う
         症例とは? 二次治療をどうする?
      2) 一次治療としてFOLFIRI+Cmab療法を行う症例とは?
        二次治療をどうする?
      3) 一次治療としてFOLFOX+Cmab/Pmab療法を行う症例とは?
        二次治療をどうする?
      4) 一次治療としてFOLFOXIRI(+Bmab)療法を行う症例とは?
        二次治療をどうする?
      5) 一次治療としてsLV5FU2/Cape+Bmab 療法を行う症例とは?
        二次治療以降をどうする?

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.11 掲載の参考文献
1) 公益財団法人がん研究振興財団編 : がんの統計 '13 (www.fpcr.or.jp/publication/pdf/gantoukei13.pdf)
2) 大腸癌研究会編 : 大腸癌治療ガイドライン 医師用 2014年版, 金原出版, 2014
4) de Gramont, A et al : Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol 15 : 808-815, 1997
5) Shimada, Y et al : Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11 (5) : 909-913, 1993
6) Saltz, LB et al : Irinotecan plus fluorouracil and leucovorin for Metastatic Colorectal Cancer. N Engl J Med 343 : 905-914, 2000
7) Douillard, JY et al : Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer : a multicentre randomised trial. Lancet 355 : 1041-1047, 2000
8) de Gramont, A et al : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (16) : 2938-2947, 2000
9) Goldberg, RM et al : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (1) : 23-30, 2004
10) Muro, K et al : Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer : a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11 : 853-860, 2010
11) Yamada, Y et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14 (13) : 1278-1286, 2013
12) Saltz, LB et al : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : A randomized phase III study. J Clin Oncol 26 : 2013-2019, 2008
13) Petrelli, F et al : FOLFIRI-bevacizumab as firstline chemotherapy in 3500 patients with advanced colorectal cancer : a pooled analysis of 29 published trials. Clin Colorectal Cancer 12 : 145-151, 2013
14) Bennouna, J et al : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) : a randomised phase 3 trial. Lancet Oncol 14 : 29-37, 2013
15) Van Cutsem, E et al : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 : 1408-1417, 2009
16) Heinemann, V et al : FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) : a randomised, open-label, phase 3 trial. Lancet Oncol 15 (10) : 1065-1075, 2014
17) Venook, AP et al : CALGB/SWOG 80405 : Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32 : 5s (suppl ; abstr LBA3), 2014
18) Douillard, JY et al : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 : 1023-1034, 2013
19) Grothey, A et al : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 : 303-312, 2013
20) Yoshino, T et al : TAS-102 monotherapy for pretreated metastatic colorectal cancer : a doubleblind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13 : 993-1001, 2012
P.13 掲載の参考文献
1) Folprecht, G et al : Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab : the CELIM randomised phase 2 trial. Lancet Oncology 11 : 38-47, 2010
2) Wong, RD et al : A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncology 22 : 2042-2048, 2011
3) Uetake, H et al : A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC 0808). Annals Surg Oncol 2014 in press
4) Adam, R et al : Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy : a model to predict long-term survival. Ann Surg 240 : 644-657, 2004
5) Uetake, H et al : High pathological CR rate and low recurrence rate was observed in liver metastasis of colorectal cancer after preoperative bevacizumab plus FOLFOX therapy. Cancer Research 71 : 3218, 2011
6) Klinger, M et al : Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17 : 2059-2065, 2010
7) Ribero, D et al : Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110 : 2761-2767, 2007
P.15 掲載の参考文献
1) McCleary, NJ et al : Refining the chemotherapy approach for older patients with colorectal cancer. J Clin Oncol 32 (20) : 2570-2580, 2014
2) Lieu, CH et al : Association of Age With Survival in Patients With Metastatic Colorectal Cancer : Analysis From the ARCAD Clinical Trials Program. J Clin Oncol, 2014 [Epub ahead of print]
3) Hurria, A et al : Predicting chemotherapy toxicity in older adults with cancer : a prospective multicenter study. J Clin Oncol 29 (25) : 3457-3465, 2011
4) Papamichael, D et al : Treatment of colorectal cancer in older patients. International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol, 2014 [Epub ahead of print]
P.23 掲載の参考文献
1) 大腸癌研究会編 : 大腸癌治療ガイドライン 医師用 2014年版, 金原出版, 2014
2) http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
3) Schmoll, HJ et al : ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23 (10) : 2479-2516, 2012
4) Bennouna, J et al : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) : a randomised phase 3 trial. Lancet Oncol 14 : 29-37, 2013
5) Falcone, A et al : Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as firstline treatment for metastatic colorectal cancer : the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 : 1670-1676, 2007
6) Tebbutt, NC et al : Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer : results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28 : 3191-3198, 2010
7) Muro, K et al : Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer : a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11 : 853-860, 2010
8) Grothey, A et al : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 : 303-312, 2013
9) Yoshino, T et al : Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. PLS-4, plenary session at Japanese Society of Medical Oncology 2012
10) Yamada, Y et al : Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) : Japanese sub-group analysis. O2-035, Japanese Society of Medical Oncology 2013
11) Cunningham, D et al : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (4) : 337-345, 2004
12) Andre, T et al : Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy : a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 24 (2) : 412-419, 2013
13) Yamada, Y et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14 (13) : 1278-1286, 2013
14) Hong, YS et al : S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer : a randomised, non-inferiority phase 3 trial. Lancet Oncol 13 (11) : 1125-1132, 2012
15) Douillard, JY et al : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 : 1023-1034, 2013
16) Peeters, M et al : Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). ASCO Gastrointestinal Cancers Symposium 2014 #LBA387
17) Patterson, SD et al : Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase 3 metastatic colorectal cancer (mCRC) study (20020408). ASCO Annual Meeting 2013 #3617
18) Bokemeyer, C et al : Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. ASCO Annual Meeting 2014 #3505
19) Stintzing, S et al : Analysis of KRAS/NRAS and BRAF mutations in FIRE-3. ESMO 2013 #LBA17
20) Schwartzberg, LS et al : PEAK : a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32 (21) : 2240-2247, 2014
21) Ciardiello, F et al : Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. ASCO Annual Meeting 2014 #3506
22) Yoshino, T et al : TAS-102 monotherapy for pretreated metastatic colorectal cancer : a doubleblind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13 (10) : 993-1001, 2012
23) Yoshino, T et al : Results of a multicenter, randomized, double-blind, phase III study of TAS-102 vs placebo, with best supportive care in patients with metastatic colorectal cancer refractory to standard therapies. Ann Oncol 25 (suppl 2) : 114, 2014
24) Falcone, A et al : FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts) : Results of the phase III TRIBE trial by GONO group. ASCO Annual Meeting 2013 #3505
25) Loupakis, F et al : Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. ASCO Annual Meeting 2014 #3519
P.25 掲載の参考文献
2) Cheng, BQ et al : Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm : a randomized controlled trial. JAMA 299 : 1669-1677, 2008
P.27 掲載の参考文献
1) 関裕志ほか : 大腸癌肝転移に対するリザーバー肝動注化学療法. Radiology Frontier 10 : 75-81, 2007
2) Mocellin, S et al : Meta-Analysis of Hepatic Arterial Infusion for Unresectable Liver Metastases From Colorectal Cancer : The End of an Era? J Clin Oncol 25 : 5649-5654, 2007
3) 森武生 : 厚生労働省がん研究助成金 平成13年度がん研究助成金計画研究 10-11 (加藤班) 「大腸がんの肝・肺転移例に対する治療法の確立に関する研究」, 2002
4) 荒井保明 : 肝動注化学療法-IVRがもたらした概念の変貌-. 医学のあゆみ 187 : 553-556, 1998

II 副作用マネジメント

P.33 掲載の参考文献
1) 日本臨床腫瘍学会 : 発熱性好中球減少症 (FN) 診療ガイドライン, 南江堂, 2012
2) Bodey, GP : Unusual presentations of infection in neutropenic patients. International Journal of Antimicrobial Agents 16 (2) : 93-95, 2000
3) Schiffer, CA et al : Platelet transfusion for patients with cancer : clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology 19 (5) : 1519-1538, 2001
4) Minami, H et al : Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese : roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17 (7) : 497-504, 2007
5) Smith, TJ et al : 2006 update of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. Journal of Clinical Oncology 24 (19) : 3187-3205, 2006
6) Hartmann, LC et al : Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336 : 1776-1780, 1997
7) Kohne, CH et al : Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer : European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21 (20) : 3721-3728, 2003
P.37 掲載の参考文献
1) 日本癌治療学会編 : 制吐薬適正使用ガイドライン 2010年5月, 第1版, 金原出版, 2010
2) Hesketh, PJ : Chemotherapy-induced nausea and vomiting. N Engl J Med 358 : 2482-2494, 2008
3) Roila, F et al : Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting : results of the Perugia consensus conference. Ann Oncol 21 : 232-243, 2010
4) Basch, E et al : Antiemetics : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29 : 4189-4198, 2011
5) NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 1. 2014
P.41 掲載の参考文献
1) 重篤副作用疾患別対応マニュアル 抗がん剤による口内炎, 厚生労働省, 2009年
2) Sonis, ST et al : Perspectives on cancer therapy-induced mucosal injury. Cancer supplement 100 : 1995-2025, 2004
3) Sonis, ST : Mucositis : The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncology 45 : 1015-1020, 2009
4) Rubenstein, EB et al : Clinical practice guideline for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer supplement 100 : 2026-2046, 2004
P.45 掲載の参考文献
1) 遠藤一司監修 : がん薬物療法の支持療法マニュアル, 第1版, 南江堂, 東京, 22, 2013
2) Richardson, G : Chemotherapy induced diarrhea. J Oncol Pharm Pract 13 : 181-198, 2007
3) Benson, AB 3rd et al : Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22 : 2918-2926, 2004
4) 小林国彦 : 下痢対策. 癌と化学療法 30 (6) : 765-771, 2003
P.50 掲載の参考文献
1) Zuehlke, RK : Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 148 (2) : 90-92, 1974
2) Komamura, H et al : Three cases of chemotherapyinduced acral erythema. J Dermatol 22 (2) : 116-121, 1995
3) 山崎直也 : がん治療を目的とした分子標的治療薬に起因する皮膚障害-分子標的治療薬の台頭とこれに伴って出現する皮膚障害の現状-. Dermatology Today 10 : 12-17, 2012
4) 設楽紘平, ほか : 副作用対策 (1) 手足症候群. 大腸癌に対するレゴラフェニブ, メディカルレビュー社, 43-48, 2013
5) 荒井邦佳, ほか : TS-1投与後早期にHand-Foot Syndromeが発症した再発胃癌の1 例. 癌と化学療法 30 (5) : 699-702, 2003
6) 山崎直也 : 【癌治療におけるCapecitabine】CapecitabineとHand-Foot Syndrome. 癌治療と宿主 16 (2) : 42-45, 2004
7) Diasio, RB : Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park) 13 (7 suppl 3) : 17-21, 1999
8) 山崎直也, ほか : 五感の生理, 病理と臨床 痛覚 痛覚を含む Hand-foot syndrome 抗癌剤によって起こる知覚障害. 医学のあゆみ 216 (3) : 257-260, 2006
9) Lacouture, ME et al : Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19 (11) : 1955-1961, 2008
10) 山崎直也 : がん治療を目的とした分子標的治療薬に起因する皮膚障害-分子標的治療薬によって起こる皮膚障害と対策-. Dermatology Today 11 : 12-19, 2013
11) 西田俊朗, ほか編 : 血管新生阻害薬のベストマネジメント-癌治療と副作用対策, 金原出版, 109-113, 2011
P.55 掲載の参考文献
1) Hynes, NE et al : ERBB receptors and cancer : the complexity of targeted inhibitors. Nat Rev Cancer 5 (5) : 341-354, 2005
2) 山崎直也 : 薬剤性皮膚障害への対策 新規分子標的治療薬の副作用を中心に. 日経メディカルCancer Review 12 : 43-47, 2008
3) 清原祥夫 : 分子標的薬による皮膚障害とその対策. 臨床外科 67 (7) : 869-877, 2012
4) 山崎直也 : 分子標的薬剤によっておこる皮膚症状と対策. Visual Dermatology 11 (7) : 756-761, 2012
5) 山崎直也 : 分子標的薬剤によって起こる皮膚症状と対策 (特集 固型腫瘍領域と血液腫瘍領域のクロストーク : 新薬開発と合併症管理). 血液・腫瘍科 61 : 564-569, 2010
6) 山崎直也 : がん治療を目的とした分子標的治療薬に起因する皮膚障害-分子標的治療薬によって起こる皮膚障害と対策-. Dermatology Today 11 : 12-19, 2013
7) 山崎直也 : 10.手足皮膚反応・口内炎・歯肉炎 (粘膜障害). 西田俊朗, ほか編, 血管新生阻害薬のベストマネジメント, 金原出版, 109-113, 2011
8) Lacouture, ME et al : Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28 (8) : 1351-1357, 2010
P.57 掲載の参考文献
1) Tournigand, C et al : OPTIMOX1 : a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 24 : 394-400, 2006
2) Chibaudel, B et al : Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27 : 5727-5733, 2009
3) Okita, NT et al : A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Invest New Drugs 30 : 2026-2031, 2012
4) Smith, EM et al : Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial. JAMA 309 : 1359-1367, 2013
5) Loprinzi, CL et al : Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32 (10) : 997-1005, 2014
P.61 掲載の参考文献
1) Maindrault-Goebel, F et al : Allergic-type reactions to oxaliplatin : retrospective analysis of 42 patients. Eur J Cancer 41 : 2262-2267, 2005
2) Siu, SW et al : Hypersensitivity reactions to oxaliplatin : experience in a single institute. Ann Oncol 17 : 259-261, 2006
3) Maindrault-Goebel, F et al : High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 37 : 1000-1005, 2001
4) Rakkar, AS et al : Management of hypersensitivity reactions to oxaliplatin with SC epinephrine. Proceedings of GI ASCO : Abstr 258, 2006
5) Yanai, T et al : Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer. Anticancer Res 32 : 5521-5526, 2012
P.65 掲載の参考文献
1) Kang, SP et al : Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-Identification, prevention, and management. J Support Oncol 5 : 451-457, 2007
2) Chung, CH et al : Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose. N Eng J Med 358 : 1109-1117, 2008
3) 独立行政法人医薬品医療機器総合機構 > 医薬品関連情報 > 重篤副作用疾患別対応マニュアル (医療関係者向け) > 「アナフィラキシー」 [http://www.info.pmda.go.jp/juutoku/juutoku_index.html]
4) Chung, CH : Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13 : 725-732, 2008
5) Vogel, WH : Infusion reactions : Diagnosis, assessment, and management. Clin J Oncol Nurs 14 : E10-21, 2010
P.69 掲載の参考文献
1) Kudoh, S et al : Interstitial lung disease in Japanese patients with lung cancer : a cohort and nested case-control study. Am J Respir Crit Care Med 12 : 1348-1357, 2008
2) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き作成委員会編 : 薬剤性肺障害の診断・治療の手引き, 第1版, 日本呼吸器学会, 東京, 12-32, 2012
3) Ohnishi, H et al : Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 58 : 872-875, 2003
P.74 掲載の参考文献
1) Nakano, H et al : Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247 (1) : 118-124, 2008
2) Kishi, Y et al : Extended preoperative chemotherapy dose not improve pathologic response and in creases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17 (11) : 2870-2876, 2010
3) Vauthey, JN et al : Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (13) : 2065-2072, 2006
4) Yashino, T et al : Randomized phase III trial of regorafenib in metastatic colorectal cancer : analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs ; doi : 10.1007/s10637-014-0154-x
5) Umemura, T et al : Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan.Clin Infect Dis 47 (5) : e52-56, 2008
6) Hui, CK et al : Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 (1) : 59-68, 2006
7) 河田純男 : 非アルコール性脂肪性肝疾患 (NAFLD) の病態と治療. 日本内科学会雑誌 101 (3) : 662-668, 2012
P.78 掲載の参考文献
1) Ishiguro, M et al : A Japanese post-marketing surveillance of cetuximab (Erbitux(R)) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 42 (4) : 287-294, 2012
2) Boku, N et al : Panitumumab in Japanese patients with unresectable colorectal cancer : a post-marketing surveillance study of 3085 patients. Jpn J Clin Oncol 44 (3) : 214-223, 2014
3) Tejpar, S et al : Magnesium wasting associated with epidermal-growth factor receptor-targeting antibodies in colorectal cancer : a prospective study. Lancet Oncol 8 : 387-394, 2007
4) Price, T et al : ASPECCT : a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). ESMO 2013
5) 中本恵理, ほか : Cetuximab投与後に生じる低マグネシウム血症の発現頻度と発現時期の調査とその対策. 医療薬学 37 (7) : 403-409, 2011
P.79 掲載の参考文献
1) Koizumi, W et al : S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol 9 : 215-221, 2008
2) 坂井譲ほか : TS-1(R) による涙道障害の多施設研究. 臨眼 66 (3) : 271-274, 2012
3) Kim, N et al : Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol 23 : 2065-2071, 2012
4) 北村祥貴ほか : S-1 療法により流涙を認めた症例の検討. 癌と化学療法 38 (2) : 259-262, 2011
5) 細谷友雅ほか : 抗がん剤による角膜および涙道の障害. 眼科 54 (1) : 27-32, 2012
6) Sakaki, T et al : Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol 56 : 214-218, 2012
P.82 掲載の参考文献
1) Scappaticci, FA et al : Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 : 1232-1239, 2007
2) 中外製薬 > 製品情報 > 特定使用成績調査集計結果. http://www.chugai-pharm.co.jp
3) Cassidy, J et al : XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer : NO16966 updated results. Br J Cancer 105 : 58-64, 2011
4) Yamada, Y et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14 : 1278-1286, 2013
5) Van Cutsem, E et al : Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer : the BEAT study. Ann Oncol 20 : 1842-1847, 2009
P.87 掲載の参考文献
1) Hryniuk, WM : The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 121-141, 1988
2) Hryniuk, WM et al : The calculation of received dose intensity. J Clin Oncol 8 : 1935-1937, 1990
3) Bonadonna, G et al : Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer : the results of 20 years of follow-up. N Engl J Med 332 : 901-906, 1995
4) Bonneterre, J et al : Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer : 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23 : 2686-2693, 2005
5) Martin Smoragiewicz, KRJ et al : British Columbia Cancer Agency, Vancouver, BC, Canada : Dose intensity and survival outcomes with adjuvant FOLFOX for colon cancer. J Clin Oncol 32, 2014 (suppl 3 ; abstr 423)
6) Carneiro, AF et al : Colon cancer adjuvant mFOLFOX-6-survival impact of oxaliplatin reduced dose-intensity. ESMO 2012 : abst #1142, 2012
7) Grothey, A et al : Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23 : 9441-9442, 2005
8) Tournigand, C et al : OPTIMOX1 : a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 24 : 394-400, 2006

III 治療変更の考え方

P.94 掲載の参考文献
1) Grothey, A : Oxaliplatin-safety profile : neurotoxicity. Semin Oncol 30 : 5-13, 2003
2) Yamada, Y et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14 : 1278-1286, 2013
3) Folprecht, G et al : Neoadjuvant treatment of unresectable colorectal liver metastases : correlation between tumor response and resection rates. Ann Oncol 16 : 1311-1319, 2005
4) Karoui, M et al : Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 : 1-7, 2006

IV 各論

P.99 掲載の参考文献
1) Saltz, LB et al : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a ramdomized phase III study. J Clin Oncol 26 : 2013-2019, 2008
2) Giantonio, BJ et al : Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 : 1539-1544, 2007
3) Cassidy, J et al : Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26 : 2006-2012, 2008
4) Rothenberg, ML et al : Capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer : a randomized phase III noninferiority study. Ann Oncol 19 : 1720-1726, 2008
5) Yamada, Y et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, noninferiority, randomised phase 3 trial. Lancet Oncol 14 : 1278-1286, 2013
P.102 掲載の参考文献
1) Sobrero, A et al : Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77 : 113-119, 2009
2) Bennouna, J et al : Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer : results from the phase II BEVACOLOR study. Clin Colorectal Cancer 11 : 38-44, 2012
3) Suenaga, M et al : Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. J Clin Pharmacol. doi : 10.1002/jcph.246, 2014
4) Nishina, T et al : Phase II clinical study of FOLFIRI (CPT-11 : 180 mg/m2) plus bevacizumab in FOLFOX-refractory/intolerant colorectal cancer (CR0802 study), 11th JSMO, 2014
P.107 掲載の参考文献
1) Bokemeyer, C et al : Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer. J Clin Oncol 27 : 663-671, 2009
2) Maughan, TS et al : Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer : results of the randomised phase 3 MRC COIN trial. Lancet 377 : 2103-2114, 2011
3) Folprecht, G et al : Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab : the CELIM randomised phase 2 trial. Lancet Oncol 11 : 38-47, 2010
4) Douillard, JY et al : Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLOFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer : the PRIME study. J Clin Oncol 28 : 4697-4705, 2010
5) Schwartzberg, LS et al : A randomized phase II study of mFOLFOX6 with either panitumumab or bevacizumab as first-line treatment in patients with unresectable wild-type KRAS metastatic colorectal cancer. 2013 Gastrointestinal Cancers Symposium. Abstract 446, 2013
P.111 掲載の参考文献
1) Van Cutsem, E et al : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (14) : 1408-1417, 2009
2) Peeters, M et al : Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology 25 : 107-116, 2014
3) Heinemann, V et al : Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 : A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. ESMO Annual Meeting 2013, Abstract #LBA17
4) Ichikawa, W et al : Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI) -based regimens : Interim safety analysis of a Japanese observational study. J Clin Oncology 31 (Suppl) : abstr3535, 2013
5) Lacouture, ME et al : Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28 (8) : 1351-1357, 2010
P.116 掲載の参考文献
1) Jonker, DJ et al : Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 : 2040-2048, 2007
2) Van Cutsem, E et al : Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 : 1658-1664, 2007
3) Cunningham, D et al : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 : 337-345, 2004
4) Andre, T et al : Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy : a GERCOR efficacy, tolerance, and translational molecular study. Annals of Oncology 24 : 412-419, 2013
5) Price, TJ et al : Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT) : a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15 (6) : 569-579, 2014
P.120 掲載の参考文献
1) Falcone, A et al : Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as firstline treatment for metastatic colorectal cancer : the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (13) : 1670-1676, 2007
2) Sunakawa, Y et al : A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. Oncology 82 (4) : 242-248, 2012
3) Masi, G et al : Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer : a phase 2 trial. Lancet Oncol 11 (9) : 845-852, 2010
4) Falcone, A et al : FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts) : Results of the phase III TRIBE trial by GONO group. J Clin Oncol 31, 2013 (suppl ; abstr 3505)
5) Gruenberger, T et al : Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer : Resectability and safety in OLIVIA. J Clin Oncol 31, 2013 (suppl ; abstr 3619)
6) 宇良敬ほか : 切除不能進行・再発結腸・直腸癌患者に対するFOLFOXIRI+Bev療法の第I相臨床試験, 第52回日本癌治療学会学術集会, 2014
P.123 掲載の参考文献
1) Benoist, C et al : Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 27 : 5727-5733, 2009
2) Ali, MT et al : Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC). J Clin Oncol 31 : suppl ; abstr e14683, 2013
3) Fairooz, K et al : Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 : 60-65, 2003
4) Hurwitz, HI et al : Bevacizumab in combination with fluorouracil and leucovorin : an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 : 3502-3508, 2005
5) Saltz, LB et al : Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer : Irinotecan Study Group. N Eng J Med 343 : 905-914, 2000
6) David, C et al : Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC) : results of a randomized international phase III trial (AVEX). J Clin Oncol 30 : suppl 34 ; abstr 337, 2012
P.126 掲載の参考文献
1) Wilhelm, SM et al : Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129 (1) : 245-255, 2011
2) Grothey, A et al : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (9863) : 303-312, 2013
P.130 掲載の参考文献
1) Muro, K et al : Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer : a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11 : 853-860, 2010
2) Goto, A et al : Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17 : 968-973, 2006
3) Tsunoda, A et al : Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 77 : 192-196, 2009
4) Shiozawa, M et al : A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 66 : 987-992, 2010
5) Komatsu, Y et al : Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 80 : 70-75, 2011
6) Yamada, Y et al : Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 30 : 1690-1696, 2012
7) Komatsu, Y et al : Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncol 51 : 867-872, 2012
8) Mizushima, T et al : A Phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer. Oncology 85 : 317-322, 2013
9) Kato, S et al : Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. Oncology 83 : 101-107, 2012
P.131 掲載の参考文献
1) Sugarbaker, PH et al : Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer : standard of care or an experimental approach? Lancet Oncol 13 : e362-369, 2012
2) Chibaudel, B et al : Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 27 (34) : 5727-5733, 2009
3) Koopman, M et al : Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) : the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31 : abst 3502, 2013
4) Koeberle, D et al : Bevacizumab continuation versus no continuation after first-line chemo- bevacizumab therapy in patients with metastatic colorectal cancer : a randomized phase III noninferiority trial. J Clin Oncol 31 : abst 3503, 2013
P.133 掲載の参考文献
1) Tournigand, C et al : OPTIMOX1 : A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 (3) : 394-400, 2006
P.142 掲載の参考文献
1) Heinemann, V et al : Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wildtype metastatic colorectal cancer : German AIO study KRK-0306 (FIRE-3). 2013 ASCO Annual Meeting, J Clin Oncol 31 (suppl) : abstr LBA3506, 2013
2) Venook, AP et al : CALGB/SWOG 80405 : Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). 2014 ASCO Annual Meeting, J Clin Oncol 32 (suppl) : abstr LBA3, 2014
3) National Comprehensive Cancer Network : NCCN clinical practice guidelines in Oncology, Colon Cancer V.3. 2014. (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
4) 大腸癌研究会編 : 大腸癌治療ガイドライン 医師用 2014年版, 金原出版, 2014
5) Van Cutsem, E et al : Advanced colorectal cancer : ESMO Clinical Practice Guidelines for treatment. Annals of Oncology 21 (Suppl) : v93-v97, 2010
P.143 掲載の参考文献
1) Fukunaga, H et al : Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol 12 (7) : 561-569, 2005
P.145 掲載の参考文献
1) Grothey, A : Reintroduction of oxaliplatin : a viable approach to the long-term management of metastatic colorectal cancer. Oncology 79 (5-6) : 389-399, 2010
2) Tournigand, C et al : OPTIMOX1 : a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 24 (3) : 394-400, 2006
3) Chibaudel, B et al : Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27 (34) : 5727-5733, 2009
4) Chibaudel, B et al : Platinum-sensitivity in metastatic colorectal cancer : towards a definition. Eur J Cancer 49 (18) : 3813-3820, 2013
P.153 掲載の参考文献
1) Petrelli, F et al : Cetuximab and panitumumab in KRAS wild-type colorectal cancer : a meta-analysis. Int J Colorectal Dis 26 (7) : 823-833, 2011
2) Heinemann, V et al : FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) : a randomised, open-label, phase 3 trial. Lancet Oncol 2014 Jul 31
3) Schmol, HJ et al : ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical desicion making. Ann Oncol 23 : 2479-2516, 2012
4) Giantonio, BJ et al : Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (12) : 1539-1544, 2007
5) Santini, D et al : Cetuximab rechallenge in metastatic colorectal cancer patients : how to come away from acquired resistance? Ann Oncol 23 : 2313-2318, 2012
P.155 掲載の参考文献
1) Douillard, JY et al : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 : 1023-1034, 2013
P.164 掲載の参考文献
1) Schmoll, HJ et al : ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology 23 : 2479-2516, 2012
2) Saltz, LB et al : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : A randomized phase III study. J Clin Oncol 26 : 2013-2019, 2008
3) Van Cutsem, E et al : Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer : Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol 29 : 2011-2019, 2011
4) Bokemeyer, C et al : Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic cancer : the OPUS study. Ann Oncol 22 : 1535-1546, 2011
5) Maughan, TS et al : Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer : results of the randomized phase 3 MRC COIN trial. Lancet 377 : 2103-2114, 2011
6) Douillard, J et al : Final results from PRIME : randomized phase III study of panitumumab with FOLFOX4 for first-line metastatic colorectal cancer. Ann Oncol 2014 Apr 8 [Epub ahead of print]
7) Van Cutsem, E et al : Outcome according to metastatic site in patients with KRAS wild-type tumors : Analysis from the CRYSTAL and OPUS studies. J Clin Oncol 29, 2011 (suppl 4 ; abstr 472)
8) Van Cutsem, E et al : Cetuximab plus FOLFIRI : Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome (Journal of Clinical Oncology, 2010 ASCO Annual Meeting Abstracts.Vol 28, No 15_suppl (May 20 Supplement), 2010 : 3570)
9) Bokemeyer, C et al : Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab : Updated data from the OPUS study. ASCO GI 2010 (Abstract No. 428)
10) Piessevaux, H et al : Early tumor shrinkage and clinical outcome in metastatic colorectal cancer : Analysis of predictive utility in the CRYSTAL and OPUS studies. JSMO 2012 (Abstract NO.IS9-3)
11) Folprecht, G et al : Tumor response and secondary respectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab : the CELIM randomized phase 2 trial. Lancet Oncol 11 : 38-47, 2010
12) Folprecht, G et al : Cetuximab and chemotherapy in the treatment of patients with initially "nonresectable" colorectal (CRC) liver metastases : Longterm follow-up of the CELIM trial. J Clin Oncol 31, 2013 (suppl ; abstr 3538)
13) Douillard, JY et al : Overall survival (OS) analysis from PRIME : Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). ASCO Annual Meeting 2013, Abstract #3620
14) Schwartzberg, LS et al : PEAK : A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. J Clin Oncol 32 (21) : 2240-2247, 2014
15) Douillard, JY et al : Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 369 : 1023-1034, 2013
16) Peeters, M et al : Impact of post-progression antivascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer : Data from the PRIME study. Makers in Cancer- A joint meeting by ASCO, EORTC and NCI : MC13-0024
P.169 掲載の参考文献
1) Falcone, A et al : Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared with Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer : The Gruppo Oncologico Nord Ovest. J Clin Oncol 25 : 1670-1676, 2007
2) Falcone, A et al : FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts) : Results of the phase III TRIBE trial by GONO group. J Clin Oncol 31 (suppl) : abstr 3505, 2013
3) Loupakis, F et al : FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50 : 57-63, 2013
4) Fornaro, L et al : Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clin Colorectal Cancer 11 : 71-76, 2012
5) Sunakawa, Y et al : A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1, *1/*6 or *1/*28. Oncology 82 : 242-248, 2012
P.170 掲載の参考文献
1) 大腸癌研究会編 : 大腸癌治療ガイドライン 2014年版, 金原出版, 2014
P.178 掲載の参考文献
1) Tebbutt, NC et al : Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer : Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28 : 3191-3198, 2010
2) Cunningham, D et al : Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previous untreated metastatic colorectal cancer (AVEX) : an open-label, randomized phase 3 trial. Lancet Oncol 14 : 1077-1085, 2013
3) Bennouna, J et al : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) : a randomized phase 3 trial. Lancet Oncol 14 : 29-37, 2013
4) Sobrero, AF et al : EPIC : Phase III trial of Cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26 : 2311-2319, 2008
5) Muro, K et al : Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer : a randomised phase 2/3 non-inferior study (FIRIS study). Lancet Oncol 11 : 853-860, 2010

最近チェックした商品履歴

Loading...